Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 35Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 26Neoplasms 16Uterine Cervical Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 10Sarcoma 9Rectal Neoplasms 9Carcinoma, Renal Cell 9Carcinoma, Hepatocellular 9Prostatic Neoplasms 8Neoplasm Metastasis 8Lymphoma 8Brain Neoplasms 8Stomach Neoplasms 7Pancreatic Neoplasms 7Oropharyngeal Neoplasms 7Multiple Myeloma 7Melanoma 7Head and Neck Neoplasms 7Glioblastoma 7Colorectal Neoplasms 7Urinary Bladder Neoplasms 6Thyroid Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Hodgkin Disease 6Colonic Neoplasms 6Salivary Gland Neoplasms 5Ovarian Neoplasms 5

Interventions

Cyclophosphamide 16Etoposide 14Carboplatin 11Temozolomide 10Vincristine 9Granulocyte Colony-Stimulating Factor 9Filgrastim 9Magnetic Resonance Spectroscopy 8Cisplatin 8etoposide phosphate 7X-Rays 7Thiotepa 7Phantoms, Imaging 7Methotrexate 7Topotecan 6Specimen Handling 6Radiotherapy 6tazemetostat 5Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Mesna 4Melphalan 4Biopsy 4palbociclib 3Sirolimus 3Nivolumab 3Leucovorin 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Rhabdoid Tumor × Fluorodeoxyglucose F18 × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡